Shares of Indivior PLC (LON:INDV – Get Free Report) were down 16% on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 729.50 ($9.22). Approximately 78,684,203 shares changed hands during mid-day trading, an increase of 2,668% from the average daily volume of 2,842,694 shares. The stock had previously closed at GBX 868 ($10.97).
Analyst Ratings Changes
Separately, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 1,800 ($22.74) target price on shares of Indivior in a research report on Tuesday, December 17th.
Get Our Latest Stock Analysis on Indivior
Indivior Stock Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- With Risk Tolerance, One Size Does Not Fit All
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- DuPont’s Electronics Spinoff: The Start of Something Big
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.